Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors
AM Taylor, BR Williams, F Giordanetto… - Journal of Medicinal …, 2023 - ACS Publications
Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has
emerged in recent years as a target of interest in oncology, both for treating with a single …
emerged in recent years as a target of interest in oncology, both for treating with a single …
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors
AM Taylor, BR Williams… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has
emerged in recent years as a target of interest in oncology, both for treating with a single …
emerged in recent years as a target of interest in oncology, both for treating with a single …
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.
AM Taylor, BR Williams, F Giordanetto… - Journal of Medicinal …, 2023 - europepmc.org
Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has
emerged in recent years as a target of interest in oncology, both for treating with a single …
emerged in recent years as a target of interest in oncology, both for treating with a single …